ABOS Acumen Pharmaceuticals - ebd bispecific antibodies show improved brain penetration compared to native anti-aβo antibodies - No hematolo
ABOS Acumen Pharmaceuticals - ebd bispecific antibodies show improved brain penetration compared to native anti-aβo antibodies - No hematological safety signals observed for acu401 in non-human primates
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.